Mechanistic insights into Old English plants

Jasminum humile inhibits calcineurin. Credit: Geoffrey Kite

Often lacking in natural product drug discovery are ‘mechanistic insights’; that is, insights into the events at the molecular level that are behind any effects that plant compounds have on cells or organisms. With this in mind, Tom Prescott screened 250 Old English plants from the Queen’s Garden at Kew, to search for compounds that inhibit the human enzyme calcineurin. The results have been published in the Journal of Ethnopharmacology.

Calcineurin plays an important role in regulating human T-cell activation in the immune response, and inhibition of this process can be beneficial in certain auto-immune diseases.

Nepeta cataria and Teucrium chamaedrys showed initial promise but the compounds responsible (phenylpropanoid glycosides) were only strongly active against the basal, un-activated form of the enzyme.

Jasminum humile was found to be more promising as the ethanol extract inhibited both isolated human calcineurin enzyme and calcineurin-dependent gene expression in yeast cells. This demonstrated that plants do indeed produce compounds that directly inhibit .

More information: Prescott, T. A. K., et al. (2011). Direct inhibition of calcineurin by caffeoyl phenylethanoid glycosides from Teucrium chamaedrys and Nepeta cataria. Journal of Ethnopharmacology 137: 1306–1310.

Prescott, T. A. K., et al. (2012). Inhibition of human calcineurin and yeast calcineurin-dependent gene expression by Jasminum humile leaf and root extracts. Journal of Ethnopharmacology 140: 293-297.

add to favorites email to friend print save as pdf

Related Stories

Time to stop giving toxic drugs to kidney transplant patients?

Sep 22, 2011

Patients who receive kidney transplants must take lifelong medications that, while preventing organ rejection, can also compromise other aspects of health. Immunosuppresive drugs called calcineurin inhibitors protect transplanted ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments